Trials / Unknown
UnknownNCT03153566
Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients
Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 20 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Cutaneous and genital warts are common dermatological conditions caused by Human Papilloma Virus. Although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several years, most patients seek treatment because the warts are unsightly and often tender or painful.
Detailed description
Genital warts are highly contagious sexually transmitted diseases (STD) caused by infection of Human Papilloma Virus and, as the most common STD in developed countries, can currently be considered to be globally epidemic. It is estimated that the frequency of Human Papilloma Virus infection among women in the world ranges from 2% to 44%. The conventional modalities in treatment of warts include destructive therapies such as salicylic acid, trichloroacetic acid, cryotherapy, silver nitrate, phenol, cantharidin, surgical interventions and laser, antiproliferative agents such as bleomycin, vitamin D analogs, podophyllin, 5 fluorouracil and antiviral agents such as cidofovir and retinoids. There are different mechanisms have been proposed for the resolution of warts with skin test antigens such as mumps, candida, trichophyton both at the injected as well as distant sites. Tuberculin: Purified protein derivative or tuberculin stimulates the cell mediated immunity non specifically by activating T helper 1 cells, Natural Killer cells, and cytokine production an increase in interleukin-12 as a process in boosting the cell-mediated immunity contributes to the mechanism of action.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | tuberculin | inject the mother wart with .3 ml tuberculin vaccine every 2 weeks |
| DEVICE | cryotherapy | 10 sec 1 cycle into all genital warts |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2018-06-01
- Completion
- 2018-12-01
- First posted
- 2017-05-15
- Last updated
- 2017-05-17
Source: ClinicalTrials.gov record NCT03153566. Inclusion in this directory is not an endorsement.